22 May 2013
Keywords: Sorrento Therapeutics, IGDRASOL, Acquisition option, Breast cancer, NSCLC
Article | 08 March 2013
USA-based Sorrento Therapeutics, Inc. (SRNE: OB) has signed an exclusive option to acquire IGDRASOL, a private company focused on the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
8 March 2013
7 March 2013
21 May 2013
© 2013 thepharmaletter.com